A REVISED FLUOROMETRIC ASSAY FOR GAUCHER’S DISEASE USING CONDURITOL-β-EPoxide WITH LIVER AS THE SOURCE OF β-GLUCOSIDASE

LYDIA B. DANIELS a, ROBERT H. GLEW a,*, NORMAN S. RADIN b and RANGA R. VUNNAM b

a Department of Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261 (U.S.A.) and b Department of Psychiatry, Mental Health Research Institute, University of Michigan, Ann Arbor, MI 48109 (U.S.A.)

(Received January 9th, 1980)

Summary

To date, enzymatic diagnosis of Gaucher’s disease via a fluorometric assay procedure which utilizes 4-methylumbelliferyl-β-D-glucopyranoside as a substrate has not been possible when liver serves as the source of enzyme since currently employed fluorometric procedures cannot adequately differentiate between a broad-specificity β-glucosidase and lysosomal glucocerebrosidase activities in crude extracts of liver. Incorporation of conduritol-β-epoxide into the incubation medium for the fluorometric assay allows one to selectively measure the glucocerebrosidase activity present in a given liver extract. In five cases of Gaucher’s disease this revised fluorometric procedure proved as effective as the assay procedure which utilizes authentic, radiolabeled glucocerebroside as the substrate in demonstrating a deficiency of glucocerebrosidase activity in liver.

Introduction

Gaucher’s disease is an autosomal recessive, inborn error in the pathway of sphingoglycolipid metabolism. The disease is characterized by a marked deficiency of glucocerebrosidase activity in all tissues that have been examined, including liver, brain, spleen, fibroblasts and leukocytes [1]. The definitive diagnosis of Gaucher’s disease rests on demonstrating a marked deficiency of glucocerebrosidase activity in tissue extracts using the radiolabeled natural substrate in an enzymatic assay [1]. This assay, however, is time-consuming and requires expensive, specialized equipment. A second and more convenient diag-

* To whom correspondence should be addressed.
nostic assay is available which utilizes the non-physiologic fluorogenic sub-
strate, 4-methylumbelliferyl-β-D-glucopyranoside (MUG). This fluorometric 
assay has been shown to give comparable results to those obtained using the 
authentic substrate-dependent assay when applied to specific tissues, most 
often leukocytes and fibroblasts [2].

The success of the fluorometric assay depends on how effectively it disting-
ishes between the two β-glucosidase activities which are present in most 
human tissues [3]. One β-glucosidase is relatively non-specific and cleaves a 
variety of glycosidic residues from the 4-methylumbelliferone moiety including 
β-D-glucose, β-D-galactose, α-L-arabinose and β-D-fucose but it will not catalyze 
the hydrolysis of glucose from glucocerebroside. The second β-glucosidase is 
glucocerebrosidase and it catalyzes the cleavage of glucose from both glucocere-
broside and MUG, but is unreactive toward other fluorogenic glycosides. For 
tissues that contain both β-glucosidases the ability of the fluorometric assay to 
detect a deficiency in glucocerebrosidase activity depends on adjusting the 
assay conditions such that the broad-specificity β-glucosidase is inhibited, there-
by permitting an accurate determination of residual glucocerebrosidase activity 
[2,4--8].

The ratio of non-specific β-glucosidase activity to glucocerebrosidase activity 
varies among tissues; there is essentially no broad-specificity β-glucosidase in 
fibroblasts, the ratio is about 30 : 70 in leukocytes, 7 : 93 in spleen, 17 : 83 in 
brain, and 83 : 17 in liver (see text). It follows that the tissues with the lowest 
levels of non-specific β-glucosidase activity, particularly fibroblasts, are the best 
sources of enzyme for the fluorometric assay. Other tissues can be used for 
diagnostic purposes as long as the assay conditions are adjusted such that non-
specific β-glucosidase activity is completely inhibited.

Recently, it was reported that the various fluorometric diagnostic assays give 
ambiguous results when liver is the source of the enzyme [3,9]. The problem 
with using a fluorometric assay is that liver is a particularly rich source of the 
non-specific β-glucosidase. In cases of Gaucher’s disease where the non-specific 
β-glucosidase is elevated, a significant proportion of the activity measured will 
not be affected by the different inhibitors used in the various fluorometric 
assays [3]. The end result is that the fluorometric assay will often demonstrate 
normal or near-normal levels of residual MUG hydrolase activity in extracts of 
tissue from these patients but a profound deficiency of glucocerebrosidase 
activity when assayed using the authentic, radiolabeled substrate.

There will continue to be occasions when a liver biopsy will be submitted as 
the source of enzyme for diagnostic purposes in cases where there is a suspicion 
of a storage disorder. Such cases present frequently enough to have stimulated 
us to try to improve the conditions of the fluorometric assay so that it could be 
applied with confidence to liver. Conduritol-β-epoxide (CBE) is a potent, 
irreversible competitive inhibitor of various plant β-glucosidases and mam-
malian glucocerebrosidase [10–15]. We recently found that the activity of the 
non-specific β-glucosidase was unaffected by concentrations of CBE which 
completely inhibited glucocerebrosidase activity. In light of this information 
we wished to determine if CBE could be used to improve the effectiveness of 
the fluorometric assay for Gaucher’s disease when liver served as the source of 
enzyme.
The standard fluorometric assay measures glucocerebrosidase activity plus whatever residual non-specific β-glucosidase activity that is not inhibited by sodium taurocholate. The addition of CBE to the standard assay completely inhibits glucocerebrosidase activity, so that the resulting β-glucosidase measurement determines only the residual non-specific β-glucosidase activity. Therefore, if one subtracts the results of fluorometric assays performed in the presence of CBE from those obtained in the absence of CBE, the difference will be a measure of relative β-glucocerebrosidase activity.

The present report describes an improved fluorometric assay for Gaucher's disease that includes CBE.

Materials

Pure sodium taurocholate from ICN Pharmaceuticals, Inc., 4-methylumbelliferyl-β-D-glucopyranoside from Koch-Light Laboratories, Ltd., [1-14C]stearic acid (56.7 mCi/mmol) from ICN Isotope and Nuclear Division of ICN Pharmaceuticals, Inc., Unisil (activated silicic acid, 200–325 mesh) from Clarkson Chemical Co., conduritol-β-epoxide was prepared according to Legler [11], and [N-stearoyl-14C]glucocerebroside was prepared according to the method of Erickson and Radin [16] and was diluted with unlabeled glucocerebroside isolated from Gaucher spleen to a specific activity of 700 cpm/nmole.

Methods

Tissue samples

Normal liver obtained at autopsy provided control tissue. Individuals were confirmed as having Gaucher's disease by the finding of Gaucher cells in an aspirate of bone marrow and by their profound deficiency of leukocyte, splenic or liver glucocerebrosidase activity. Table I describes the five Gaucher patients who were studied in the present report. Tissues were stored at -70°C for 3 months to 2 years.

Tissue extraction

All procedures were carried out at 1–4°C. Liver samples (approximately 50 mg) were homogenized with the aid of a Potter-Elvehjem homogenizer in 10 volumes of 10 mmol/l sodium phosphate, pH 6.0, containing 10 mmol/l 2-mercaptoethanol and 0.02% (w/v) sodium azide. Sodium azide is added as an anti-bacterial agent to all buffers stored at room temperature. The crude homogenate was used directly for all experiments.

Enzyme assays

The standard β-glucosidase assay (Table III) contained 10 mmol/l MUG, 20 mmol/l sodium acetate, pH 5.5, and an appropriate amount of enzyme-protein (between 50–80 µg) in a final volume of 0.1 ml. All incubations were carried out for 1 h at 37°C with gentle shaking. The reaction was terminated and fluorescence determined as previously described [17]. Glucocerebrosidase activity in liver extracts was also assayed using the authentic substrate labeled in the stearoyl side chain (Table I). The assay mixture contained 79,100 cpm of
TABLE II

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Type of Gaucher's disease</th>
<th>Glucocere-brosidase activity * (units/mg)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>71</td>
<td>M</td>
<td>Adult, type I</td>
<td>7.39 [8.3] ***</td>
<td>Caucasian, Ashkenazi Jewish, death due to leukemia</td>
</tr>
<tr>
<td>2</td>
<td>1.3</td>
<td>F</td>
<td>Infantile, type II</td>
<td>0.05 [&lt; 1] **</td>
<td>Black</td>
</tr>
<tr>
<td>3</td>
<td>2.0</td>
<td>F</td>
<td>Infantile, type II</td>
<td>0.05 [&lt; 1]</td>
<td>Black</td>
</tr>
<tr>
<td>4</td>
<td>11</td>
<td>F</td>
<td>Juvenile, type III</td>
<td>0.098 [&lt; 1]</td>
<td>Caucasian</td>
</tr>
<tr>
<td>5</td>
<td>fetus</td>
<td>unknown</td>
<td>Infantile, type II</td>
<td>0.05 [&lt; 1]</td>
<td>Parents had another child with Gaucher's disease</td>
</tr>
</tbody>
</table>

* Activity determined using labeled glucocerebroside as substrate, as described in "Materials and Methods"; controls, 40.4 units/mg (±19.1).

** Described elsewhere [20].

*** The number in brackets represents percent activity relative to normal liver glucocerebrosidase activity. Control liver was obtained from 8 individuals aged 8.75—72 years who died of Friedreich's ataxia; glioblastoma multiforme; hepatic failure due to alcoholism; atherosclerosis and pulmonary embolism; chronic lymphocytic leukemia; multiple myeloma; emphysema; and pulmonary fibrosis and respiratory failure.

\[^{14}C\]gluco\textsubscript{cerebroside, 20 mmol/l sodium acetate, pH 5.5, 1.2\% (w/v) sodium taurocholate and an appropriate amount of enzyme protein (usually 0.3—0.5 mg), in a final volume of 0.1 ml. Incubations were carried out for 1 h at 37\textdegree C with gentle shaking. The product, \[^{14}C\]ceramide, was separated from unreacted substrate using silicic acid (Unisil) chromatography and quantitated as previously described [18]. Preliminary experiments showed that there was no significant difference in the results if heat-killed blanks were used instead of blanks terminated at zero hour. Consequently, zero-time blanks were used in all experiments.

One unit of enzyme activity is defined as that amount of enzyme which cleaves 1 nmol of glucose from the appropriate substrate, per hour, at 37\textdegree C.

**Protein determination**

Protein was determined by the method of Lowry et al. [19] using bovine serum albumin as standard.

**Results**

**Distribution of β-glucosidase and β-glucocerebrosidase activity in normal tissue**

Table II summarizes the distribution of β-glucosidase and glucocerebrosidase activity in the 100 000 X g supernatant and particulate fractions, respectively, derived from homogenates of normal human tissues. Liver is the only tissue in which the broad specificity β-glucosidase is the predominant enzyme, constituting 77% of the total β-glucosidase activity measured by the standard fluorometric assay. In some patients with Gaucher's disease, the deficiency of gluco-
TABLE II
DISTRIBUTION OF THE BROAD-SPECIFICITY β-GLUCOSIDASE AND GLUCOCEREBROSIDASE IN CONTROL HUMAN LIVER

<table>
<thead>
<tr>
<th>Tissue</th>
<th>β-Glucosidase activity a</th>
<th>Glucocerebrosidase c</th>
<th>β-Glucosidase: glucocerebrosidase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Soluble β-glucosidase b</td>
<td>Glucocerebrosidase</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(units/mg)</td>
<td>(units/mg)</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>374</td>
<td>76.2</td>
<td>83:17</td>
</tr>
<tr>
<td>Brain</td>
<td>2.58</td>
<td>12.2</td>
<td>17:83</td>
</tr>
<tr>
<td>Spleen d</td>
<td>3.13</td>
<td>40.5</td>
<td>7:93</td>
</tr>
<tr>
<td>Leukocytes d</td>
<td>4.21</td>
<td>9.70</td>
<td>30:70</td>
</tr>
<tr>
<td>Fibroblasts</td>
<td>2.80</td>
<td>312.8</td>
<td>0.9:99.1</td>
</tr>
</tbody>
</table>

a β-Glucosidase activity was determined as described under “Methods.”

b Soluble β-glucosidase represents activity measured in the high speed (100,000 X g) supernatant fraction using the standard β-glucosidase assay described under “Methods.”

c Glucocerebrosidase activity represents activity measured in the particulate fraction.

d Reported elsewhere [21.]

cerebrosidase in liver is associated with an increase in the level of the broad-specificity β-glucosidase thereby making liver an unsatisfactory source of enzyme for the common fluorometric diagnostic assays. Recognizing that liver biopsy material is occasionally used for diagnostic purposes when Gaucher’s disease is suspected, we tested various compounds which might act as differential inhibitors of β-glucosidase and glucocerebrosidase.

Effects of various inhibitors on β-glucosidase and β-glucocerebrosidase activity

Partially purified preparations of liver non-specific β-glucosidase and glucocerebrosidase were assayed in the presence of a variety of gluconamides, galactonamides, lactones and CBE (Table III). The results indicated that there were three classes of compounds: (1) compounds which did not inhibit either enzyme significantly, (2) those which were inhibitory but which did not distinguish between the two enzymes, and (3) one compound which significantly inhibited only one of the two enzymes. The following compounds constituted the first category: D-gluconamide, N-(6-aminohexyl)-D-gluconamide, D-glucose, D-galactonamide, D-galactonyl hydrazide, N-(2-aminoethyl)-D-galactonamide and 1,4-galactonolactone. D-gluconyl hydrazide, 1,5-gluconolactone, and hexane diamine inhibited both enzymes to different degrees, but the differences were not sufficient to allow us to extend the application of the fluorometric assay to liver. 10 mmol/l D-gluconyl hydrazide inhibited 22.5% of the glucocerebrosidase activity as compared to 47.1% of the β-glucosidase activity. 1,5-Gluconolactone (10 mmol/l) inhibited glucocerebrosidase 51.2% and β-glucosidase 93%. The same concentration of hexane diamine inhibited glucocerebrosidase activity 44.5% and β-glucosidase 6.6%. None of these compounds proved satisfactory in differentiating glucocerebrosidase and β-glucosidase activities in crude homogenates of liver. However, the results of inhibitor studies with CBE were particularly interesting and of potential practical value. When present at a concentration of 6.2 mmol/l in the standard β-glucosidase assay, CBE completely inhibited glucocerebrosidase activity but had virtually no
TABLE III
COMPARISON OF THE EFFECTS OF VARIOUS COMPOUNDS ON GLUCOCEREBROSIDASE AND BROAD-SPECIFICITY $\beta$-GLUCOSIDASE FROM CONTROL HUMAN LIVER

<table>
<thead>
<tr>
<th>Compounds added to incubation medium</th>
<th>Final concentration</th>
<th>$\beta$-Glucosidase activity $^a$</th>
<th>Glucocerebrosidase $^b$ (% of control)</th>
<th>Soluble $\beta$-glucosidase $^c$ (% of control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Sodium taurocholate</td>
<td>1.2% (w/v)</td>
<td>862</td>
<td>16.4</td>
<td></td>
</tr>
<tr>
<td>D-Gluconamide</td>
<td>10 mmol/l</td>
<td>101</td>
<td>102</td>
<td></td>
</tr>
<tr>
<td>D-Gluconyl hydrazide</td>
<td>10 mmol/l</td>
<td>75.5</td>
<td>52.9</td>
<td></td>
</tr>
<tr>
<td>N-(6-Aminohexyl)-D-guconamide</td>
<td>10 mmol/l</td>
<td>94.1</td>
<td>87.1</td>
<td></td>
</tr>
<tr>
<td>1,5-Gluconolactone</td>
<td>10 mmol/l</td>
<td>48.8</td>
<td>7.0</td>
<td></td>
</tr>
<tr>
<td>D-Glucose</td>
<td>10 mmol/l</td>
<td>90.9</td>
<td>95.5</td>
<td></td>
</tr>
<tr>
<td>D-Galactonamide</td>
<td>10 mmol/l</td>
<td>95.1</td>
<td>92.6</td>
<td></td>
</tr>
<tr>
<td>D-Galactonyl hydrazide</td>
<td>10 mmol/l</td>
<td>91.8</td>
<td>91.0</td>
<td></td>
</tr>
<tr>
<td>N-(2-Aminoethyl)-D-galactonamide</td>
<td>10 mmol/l</td>
<td>87.9</td>
<td>93.4</td>
<td></td>
</tr>
<tr>
<td>1,4-Galactonolactone</td>
<td>10 mmol/l</td>
<td>98.0</td>
<td>82.0</td>
<td></td>
</tr>
<tr>
<td>Hexane diamine</td>
<td>10 mmol/l</td>
<td>65.5</td>
<td>93.4</td>
<td></td>
</tr>
<tr>
<td>Conduritol-$\beta$-epoxide</td>
<td>6.2 mmol/l</td>
<td>0.2</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

$^a$ The standard $\beta$-glucosidase assay contained: 10 mmol/l MUG and 20 mmol/l sodium acetate, pH 5.5.

$^b$ Glucocerebrosidase was partially purified from the particulate fraction (100 000 x g, 1 h) from control human liver by column chromatography on CM-cellulose and DEAE-cellulose as described elsewhere [16]. The specific activity of the glucocerebrosidase preparation was 15.8 units/mg when assayed using the standard $\beta$-glucosidase assay in the absence of sodium taurocholate. The enzyme preparation was free of non-specific $\beta$-glucosidase activity.

$^c$ Soluble broad-specificity $\beta$-glucosidase was purified 50-fold by chromatography on QAE-Sephadex and hydroxylapatite as described elsewhere [3] from the high-speed supernatant fraction (100 000 x g, 1 h) of human liver to a specific activity of 7500 units/mg. The preparation was free of glucocerebrosidase activity.

$^d$ Control activity represents the activity in the absence of additions to the standard $\beta$-glucosidase assay.

effect on non-specific $\beta$-glucosidase activity. Even when glucocerebrosidase was assayed in the MUG-fluorometric assay in the presence of 1.2% (w/v) sodium taurocholate, CBE completely inhibited glucocerebrosidase activity. These results demonstrated that CBE might be useful in distinguishing between the two enzyme activities in a crude homogenate of liver. Additional experiments (data not shown) confirmed that the inclusion of 3–6 mmol/l CBE in the standard fluorometric $\beta$-glucosidase assay supplemented with sodium taurocholate inhibited more than 95% of the glucocerebrosidase activity present in unfractionated crude extracts of control liver. This concentration range for CBE is similar to that used by Legler [10,11] to inhibit the $\beta$-glucosidase of Aspergillus wentii.

Determinations of relative glucocerebrosidase activity in homogenates of liver from patients with Gaucher's disease

In a previous study [3] comparing various enzymatic diagnostic methods in which liver served as the source of enzyme, we demonstrated that the pH 5.5-sodium taurocholate, fluorometric $\beta$-glucosidase assay was ineffective in identifying a case of adult Gaucher's disease. On the basis of that finding, we recommended against the use of a fluorometric assay for the diagnosis of
Gaucher's disease when a liver biopsy provides the source of enzyme. Liver from that same patient (case 1) with the adult form of Gaucher's disease was included in the present study. As shown in Table IV, β-glucosidase determinations performed in the absence of CBE using the fluorogenic substrate in the pH 5.5-sodium taurocholate assay of Peters et al. [2] indicated that this patient's liver contained 16.8 units/mg of β-glucosidase activity. While this value is only 25–30% of the mean value for the control tissues, it is very close to the lower limit of the control range (19.1 units/mg). Nevertheless, the diagnosis of Gaucher's disease could be confirmed in each of the four neuropathic cases using the pH 5.5-sodium taurocholate assay first described by Peters et al. for leukocytes [2] and later for fibroblasts [3], even when the assay medium was not supplemented with CBE.

The results of incorporating CBE into the fluorometric β-glucosidase assay for Gaucher's disease are summarized in the right-hand column of Table IV under "relative glucocerebrosidase activity". Using this CBE-dependent fluorometric assay the homogenate of liver from the case of adult, non-neuropathic Gaucher's disease exhibited a level of residual glucocerebrosidase activity (5.0 units/mg, 9.6% of control mean) comparable to that obtained using the glucocerebrosidase assay that utilizes labeled glucocerebroside as the substrate (Table I, 11.7% of control mean). With this modified, CBE-dependent fluorometric assay, the liver homogenate from case 1 exhibited a relative glucocerebrosidase content that was more than 3-fold less than the lower limit of the control range (15.3 units/mg). The incorporation of CBE into the pH 5.5-sodium taurocholate β-glucosidase assay also yielded a procedure that resulted

### TABLE IV

β-GLUCOSIDASE ACTIVITY IN HOMOGENATES OF LIVER FROM CONTROLS AND PATIENTS WITH GAUCHER'S DISEASE, PERFORMED USING MUG AS THE SUBSTRATE IN THE PRESENCE AND ABSENCE OF CONDURITOL-β-EPOXIDE

<table>
<thead>
<tr>
<th>Homogenates</th>
<th>β-Glucosidase activity a</th>
<th>Relative glucocerebrosidase activity b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A minus CBE</td>
<td>B plus CBE d</td>
</tr>
<tr>
<td>Controls (n = 8)</td>
<td>19.1–105</td>
<td>3.07–24.6</td>
</tr>
<tr>
<td>range</td>
<td>61.4 (±29.1) e</td>
<td>9.3 (±7.29)</td>
</tr>
<tr>
<td>mean (±S.D.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gaucher patients</td>
<td>16.8</td>
<td>11.8</td>
</tr>
<tr>
<td>case 1</td>
<td>7.06</td>
<td>5.38</td>
</tr>
<tr>
<td>case 2</td>
<td>3.01</td>
<td>1.51</td>
</tr>
<tr>
<td>case 3</td>
<td>3.47</td>
<td>1.32</td>
</tr>
<tr>
<td>case 4</td>
<td>3.76</td>
<td>2.40</td>
</tr>
<tr>
<td>case 5</td>
<td>3.76</td>
<td>2.40</td>
</tr>
</tbody>
</table>

a The standard β-glucosidase assay was supplemented with 1.2% (w/v) sodium taurocholate.
b Relative glucocerebrosidase activity is obtained by subtracting the values in column B from those in column A.
c The number in brackets indicates residual glucocerebrosidase activity expressed as percent of the mean control value.
d "Plus CBE" indicates that the final assay medium contained 6.2 mmol/l conduritol-β-epoxide.
e The number in parentheses indicates one standard deviation.
in generally lower residual enzyme activities in the extracts of liver from all four of the neuropathic cases of Gaucher's disease. For example, according to the results obtained using the procedure of Peters et al. [17], case 2 had 12% as much hepatic β-glucosidase activity as the controls but when evaluated using the CBE-modified assay, her residual relative glucocerebrosidase activity was only 3.2% of control.

These results demonstrate that the CBE-modified fluorometric assay procedure effectively diagnoses Gaucher's disease using liver tissue as the source of enzyme.

Discussion

In the present report we have established conditions for assessing the relative glucocerebrosidase content of human liver using a fluorometric procedure, and we have demonstrated that this revised procedure can be used to confirm the diagnosis of Gaucher's disease in neuropathic and nonneuropathic cases as reliably as the assay that employs the natural substrate.

The results reported here indicate that liver can be used satisfactorily as the source of enzyme in a diagnostic fluorometric assay, thus overcoming the objections raised earlier by Ben-Yoseph and Nadler [9] and ourselves [3] concerning the reliability of the results obtained using any fluorometric β-glucosidase assay. This revised assay procedure provides a measure of glucocerebrosidase activity which is as reliable an indicator of the homozygous deficiency state as the assay that employs the authentic substrate. However, the fluorometric procedure is more amenable to routine use in the clinical laboratory because it is rapid, sensitive and does not require scintillation counting equipment. Since it is not uncommon for a clinical laboratory to receive liver biopsy material for the determination of glucocerebrosidase activity when Gaucher's disease is suspected, the need for a reliable and rapid fluorometric assay procedure is evident.

The CBE-dependent procedure described in this report may be useful in evaluating the effectiveness of glucocerebrosidase replacement therapy in Gaucher patients, since the uptake of the enzyme by the liver can be determined readily in biopsy samples.

As leukocytes from heterozygotes become available, it will be useful to evaluate the effectiveness of this revised β-glucosidase assay for carrier typing.

Conduritol-β-epoxide has been shown to be a β-glucosidase active-site reagent by other investigators [10–15]. Radin has shown that the two glucosidases in various mouse tissues show differential sensitivities to CBE [13]. We have demonstrated in this report that glucocerebrosidase and β-glucosidase from a human source are also affected differently by this inhibitor, thus adding one more property to the growing list of distinctions between these two enzymes. The soluble β-glucosidase is inhibited by sodium taurocholate and other bile salts, is inhibited by phosphatidic acid and other acidic phospholipids, has a broad substrate specificity as demonstrated using artificial substrates [2] and is unaffected by CBE. Conversely, human glucocerebrosidase is activated by sodium taurocholate as well as by phosphatidic acid and other phospholipids, acts on a very narrow range of substrates [2] and is profoundly inhibited by
CBE. This latest distinction — the different sensitivities to CBE — suggests that the active sites of these two enzymes are profoundly different. Therefore, if both enzymes are derived from a single parent gene product, post-translational modification must occur in the region of the active sites to produce two enzymes with different enzymatic-kinetic properties. If there is a precursor-product relationship between these two β-glucosidases, CBE will be a valuable tool in future studies, since it has proved so effective in discriminating between these two enzymes.

Acknowledgements

This work was supported by grants to R.H.G. from the National Institutes of Health (AM 17564) and the National Foundation, March of Dimes, and by a grant to N.S.R. from the National Institutes of Health (NS 03192).

References